SELECT PUBLICATIONS

Aballea S et al. Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the US. Proc ASCO 2005;Abstract 3532.

Allegra C, Sargent DJ. Adjuvant therapy for colon cancer — The pace quickens. N Engl J Med 2005;352(26):2746-8. No abstract available

Andre T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003;21(15):2896- 903. Abstract

Andre T et al. Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. Proc ASCO 2005;Abstract 3522.

Benson AB 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22(16):3408-19. Abstract

Bleiberg H. Adjuvant treatment of colon cancer. Curr Opin Oncol 2005;17(4):381-5. Abstract

Cassidy J et al. Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for Dukes’ C colon cancer: No differences in treatment arms that could influence survival outcome. Proc ASCO 2005;Abstract 3586.

Chang DZ, Abbruzzese JL. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. Clin Adv Hematol Oncol 2005;3(5):400-4. No abstract available

Chong G, Cunningham D. Gastrointestinal cancer: Recent developments in medical oncology. Eur J Surg Oncol 2005;31(5):453-60. Abstract

Chua Y et al. Who should be considered for FOLFOX adjuvant chemotherapy? An analysis of Dukes B colorectal cancer in a Royal Marsden Hospital randomized trial. Proc ASCO 2005;Abstract 3559.

Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005;32(1):61-8. Abstract

Cronin D et al. Patterns of care for adjuvant therapy for colorectal cancer. Proc ASCO 2005;Abstract 6080.

De Gramont A et al. Oxaliplatin/5FU/lv in the adjuvant treatment of Stage II and Stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc ASCO 2005;Abstract 3501.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.

Di Costanzo F, Doni L. Adjuvant therapy in colon cancer: Which treatment in 2005? Ann Oncol 2005;16(Suppl 4):iv69-iv73. Abstract

Diaz-Rubio Garcia E et al. A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer. Clin Transl Oncol 2005;7(1):3-11. Abstract

Ellis LM. Bevacizumab. Nat Rev Drug Discov 2005;Suppl:8-9. Abstract

Emmanouilides C et al. Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 2004;8(Suppl 1):50-2. Abstract

Ferrara N et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328-35. Abstract

Gill S et al. Pooled analysis of fluorouracilbased adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22(10):1797-806. Abstract

Gray RG et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc ASCO 2004;Abstract 3501.

Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004;5(10):2159-70. Abstract

Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30(4 Suppl 15):5-13. Abstract

Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005;23(15):3311-3. Abstract

Gunderson LL et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 2004;22(10):1785-96. Abstract

Hecht JR et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc ASCO 2005;Abstract 3.

Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer 2005;5(Suppl 1):11-8. Abstract

Hochster HS. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin’ FU (or, avoiding that oral fixation). Clin Adv Hematol Oncol 2005;3(5):405-6. No abstract available

Hotta T et al. Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Oncol Rep 2005;14(2):433-9. Abstract

Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

IMPACT Trial. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44. Abstract

Le Voyer TE et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21(15):2912-9. Abstract

Macdonald JS. Clinical overview: Adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004;54(Suppl 1):4-11. Abstract

Mancuso A, Sternberg CN. Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice? Crit Rev Oncol Hematol 2005;55(1):67-81. Abstract

Marsoni S; International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol 2001;28(1 Suppl 1):14-9. Abstract

McKendrick J, Coutsouvelis J. Capecitabine: Effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005;6(7):1231-9. Abstract

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352(5):476- 87. No abstract available

Midgley R, Kerr DJ. Adjuvant chemotherapy for stage II colorectal cancer: The time is right! Nat Clin Pract Oncol 2005;2(7):364-9. Abstract

Midgley R, Kerr D. Bevacizumab — Current status and future directions. Ann Oncol 2005;16(7):999-1004. Abstract

Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 2005;62(10):1021-32. Abstract

Nordlinger B et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: A multicentre randomised controlled phase III trial. Lancet Oncol 2005;6(7):459-68. Abstract

O’Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park) 2004;18(6):751-5; discussion 755-8. Abstract

O’Connell MJ et al. Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03. Proc ASCO 2005;Abstract 3511.

Polikoff J et al. Erbitux (Cetuximab) Plus FOLFOX for Colorectal Cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial. Proc ASCO 2005;Abstract 3574.

Sargent DJ et al; Adjuvant Colon Cancer Endpoints (ACCENT) Group. Endpoints for Colon Adjuvant Clinical Trials (CACT): Recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials. Proc ASCO 2005;Abstract 3512.

Scheithauer W et al; X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5- fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14(12):1735-43. Abstract

Schmoll HJ et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Proc ASCO 2005;Abstract 3523.

Sun W, Haller DG. Adjuvant therapy for colon cancer. Curr Oncol Rep 2005;7(3):181-5. Abstract

Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704. Abstract

Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Proc ASCO 2005;Abstract 3521.

Van Cutsem E et al. Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract

Van Cutsem E et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc ASCO 2005. Abstract

Waterston AM, Cassidy J. Adjuvant treatment strategies for early colon cancer. Drugs 2005;65(14):1935-47. Abstract

Willett CG et al. Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med 2004;10(2):145-7. Abstract

Wolmark N et al. A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc ASCO 2005. Abstract

Wolmark N et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. Proc ASCO 2004;Abstract 3508.